<DOC>
	<DOCNO>NCT00006453</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know carboplatin effective without gemcitabine ovarian epithelial cancer . PURPOSE : Randomized phase III trial compare effectiveness carboplatin without gemcitabine treat patient advanced ovarian epithelial cancer respond previous chemotherapy .</brief_summary>
	<brief_title>Carboplatin With Without Gemcitabine Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded Previous Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Compare time progression patient advance ovarian epithelial carcinoma fail prior first-line platinum-based therapy treat carboplatin without gemcitabine . - Compare response rate , duration response , survival time patient treat regimen . - Compare toxicity treatment regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord progression-free time ( 6-12 month v 12 month ) , type prior first-line therapy , bidimensionally measurable disease ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients receive carboplatin IV 30-60 minute day 1 gemcitabine IV 30-60 minute day 1 8 . - Arm II : Patients receive carboplatin IV arm I . Treatment arm repeat every 3 week 6-8 course absence disease progression unacceptable toxicity . Quality life assess baseline , subsequent chemotherapy course , 50 day study . Patients follow 50 day , every 2 month 1 year , every 3 month 1 year . PROJECTED ACCRUAL : A total 350 patient accrue study .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial carcinoma amenable curative surgery radiotherapy Evidence recurrence progression 6 month discontinuation prior firstline platinumcontaining regimen No tumor borderline malignancy Evaluable disease outside previously irradiated area No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Glomerular filtration rate great 50 mL/min Other : No concurrent active infection No primary malignancy except carcinoma situ cervix adequately treat basal cell skin cancer No concurrent serious systemic disorder PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 1 prior platinumbased chemotherapy regimen No prior gemcitabine No concurrent cytotoxic antineoplastic treatment Endocrine therapy : At least 3 week since prior hormonal therapy Concurrent hormone replacement therapy allow Concurrent steroid antiemetic allow Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy ( limited small pelvis ) Concurrent palliative radiotherapy nontarget lesion allow Surgery : See Disease Characteristics Other : At least 3 week since prior investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>